CY1112310T1 - Προφαρμακα κομπρεταστατινης α1-φωσφορικης και κομπρεταστατινης β1-φωσφορικης - Google Patents

Προφαρμακα κομπρεταστατινης α1-φωσφορικης και κομπρεταστατινης β1-φωσφορικης

Info

Publication number
CY1112310T1
CY1112310T1 CY20111101232T CY111101232T CY1112310T1 CY 1112310 T1 CY1112310 T1 CY 1112310T1 CY 20111101232 T CY20111101232 T CY 20111101232T CY 111101232 T CY111101232 T CY 111101232T CY 1112310 T1 CY1112310 T1 CY 1112310T1
Authority
CY
Cyprus
Prior art keywords
compretastatin
compresstatatine
phosphorate
phosphate
prodrugs
Prior art date
Application number
CY20111101232T
Other languages
English (en)
Inventor
George R Pettit
John W Lippert Iii
Original Assignee
Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University filed Critical Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University
Publication of CY1112310T1 publication Critical patent/CY1112310T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/42—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms
    • C07C255/43—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms the carbon skeleton being further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/18—Aralkyl radicals
    • C07D217/20—Aralkyl radicals with oxygen atoms directly attached to the aromatic ring of said aralkyl radical, e.g. papaverine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C07D453/04—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems having a quinolyl-4, a substituted quinolyl-4 or a alkylenedioxy-quinolyl-4 radical linked through only one carbon atom, attached in position 2, e.g. quinine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/12—Esters of phosphoric acids with hydroxyaryl compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Η παρούσα εφεύρεση σχετίζεται με τις συνθέσεις και τη δομική αποσαφήνιση Προφαρμάκων Κομπρεταστατίνης Α1-Φωσφορικής και Προφαρμάκων Κομπρεταστατίνης Β1-Φωσφορικής και τη χρησιμοποίηση εκείνων των προφαρμάκων στην αντιμετώπιση νεοπλασματικών νόσων. Τα προφάρμακα που περιγράφονται στο παρόν έχουν τη δομή : Προφάρμακο Κομπρεταστίνης Α-1 Φωσφορικής (Ι) και Προφάρμακα Κομπρεταστίνης Β-1 Φωσφορικής (ΙΙ).
CY20111101232T 2000-04-27 2011-12-12 Προφαρμακα κομπρεταστατινης α1-φωσφορικης και κομπρεταστατινης β1-φωσφορικης CY1112310T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20039500P 2000-04-27 2000-04-27
EP01928978A EP1278758B1 (en) 2000-04-27 2001-04-27 Combretastatin A-1 phosphate and Combretastatin B-1 phosphate prodrugs

Publications (1)

Publication Number Publication Date
CY1112310T1 true CY1112310T1 (el) 2015-12-09

Family

ID=22741540

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111101232T CY1112310T1 (el) 2000-04-27 2011-12-12 Προφαρμακα κομπρεταστατινης α1-φωσφορικης και κομπρεταστατινης β1-φωσφορικης

Country Status (9)

Country Link
US (1) US7078552B2 (el)
EP (1) EP1278758B1 (el)
AT (1) ATE527271T1 (el)
CA (1) CA2407675C (el)
CY (1) CY1112310T1 (el)
DK (1) DK1278758T3 (el)
ES (1) ES2395097T3 (el)
PT (1) PT1278758E (el)
WO (1) WO2001081355A1 (el)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1278758E (pt) * 2000-04-27 2011-12-22 Univ Arizona Pró-fármacos de fosfato de combretastatina a-1 e fosfato de combretastatina b-1
CA2463902A1 (en) 2001-10-26 2003-05-01 Oxigene, Inc. Functionalized stilbene derivatives as improved vascular targeting agents
AU2004218412A1 (en) 2003-02-28 2004-09-16 Oxigene, Inc. Compositions and methods with enhanced therapeutic activity
US20090137687A1 (en) * 2003-02-28 2009-05-28 Oxigene, Inc. Compositions and Methods With Enhanced Therapeutic Activity
GB0504994D0 (en) 2005-03-11 2005-04-20 Biotica Tech Ltd Novel compounds
CN1907989B (zh) * 2005-08-02 2011-08-17 浙江天皇药业有限公司 毛兰素盐及其制备方法和包含其的药物组合物
NZ577130A (en) * 2006-12-07 2010-11-26 Univ China Medical Novel hydrophilic derivatives of 2-aryl-4-quinolones as anticancer agents
US20090012325A1 (en) * 2007-02-22 2009-01-08 Ajith Manage Methods for preparing phosphoric acids of combrestastatin and derivatives thereof
JP5302328B2 (ja) * 2007-11-21 2013-10-02 オキシジーン， インコーポレイテッド 造血性新生物を治療するための方法
WO2010132498A1 (en) * 2009-05-11 2010-11-18 Oxigene, Inc. Vascular disrupting agents for treatment of polypoidal choroidal vasculopathy
CA2790407A1 (en) * 2010-03-11 2011-09-15 Oxigene, Inc. Ophthalmic formulations
WO2011151423A1 (en) 2010-06-04 2011-12-08 Exonhit S.A. Substituted isoquinolines and their use as tubulin polymerization inhibitors
US9353150B2 (en) 2012-12-04 2016-05-31 Massachusetts Institute Of Technology Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
US10201623B2 (en) 2013-03-15 2019-02-12 Memorial Sloan Kettering Cancer Center HSP90-targeted cardiac imaging and therapy
WO2016130969A1 (en) 2015-02-13 2016-08-18 George Robert Pettit Silstatin compounds
EP3337495A4 (en) 2015-08-18 2019-04-10 Mateon Therapeutics, Inc. USE OF VDA TO ENHANCE IMMUNOMODULATION THERAPIES AGAINST TUMORS
US10918627B2 (en) 2016-05-11 2021-02-16 Massachusetts Institute Of Technology Convergent and enantioselective total synthesis of Communesin analogs
US11932650B2 (en) 2017-05-11 2024-03-19 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
WO2019094709A1 (en) 2017-11-09 2019-05-16 Pettit George R Betulastatin compounds
WO2020247054A1 (en) 2019-06-05 2020-12-10 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1338645C (en) * 1987-01-06 1996-10-15 George R. Pettit Isolation, structural elucidation and synthesis of novel antineoplastic substances denominated "combretastatins"
GB9106177D0 (en) 1991-03-22 1991-05-08 Aston Molecules Ltd Substituted diphenylethylenes and analogues or derivatives thereof
US5561122A (en) 1994-12-22 1996-10-01 Arizona Board Of Regents Acting On Behalf Of Arizona State University Combretastatin A-4 prodrug
US7018987B1 (en) * 1998-01-09 2006-03-28 Arizona Broad of Regents acting for and on behalf of Arizona State University Synthesis of combretastatin A-4 prodrugs and trans-isomers thereof
JP2002500184A (ja) * 1998-01-09 2002-01-08 アリゾナ ボード オブ リーゼンツ フェンスタチンとそのプロドラッグの合成
GB9903403D0 (en) 1999-02-16 1999-04-07 Angiogene Pharm Ltd Substituted stilbene compounds with vascular damaging activity
WO2000048606A1 (en) * 1999-02-18 2000-08-24 Oxigene, Inc. Compositions and methods for use in targeting vascular destruction
PT1278758E (pt) * 2000-04-27 2011-12-22 Univ Arizona Pró-fármacos de fosfato de combretastatina a-1 e fosfato de combretastatina b-1

Also Published As

Publication number Publication date
CA2407675C (en) 2012-07-10
ATE527271T1 (de) 2011-10-15
EP1278758A1 (en) 2003-01-29
US20030220298A1 (en) 2003-11-27
DK1278758T3 (da) 2012-01-23
US7078552B2 (en) 2006-07-18
EP1278758B1 (en) 2011-10-05
WO2001081355A1 (en) 2001-11-01
EP1278758A4 (en) 2005-10-19
CA2407675A1 (en) 2001-11-01
PT1278758E (pt) 2011-12-22
ES2395097T3 (es) 2013-02-08

Similar Documents

Publication Publication Date Title
CY1112310T1 (el) Προφαρμακα κομπρεταστατινης α1-φωσφορικης και κομπρεταστατινης β1-φωσφορικης
DK1914237T3 (da) Antivirale fosfonatesterforbindelser
ES2176343T3 (es) Composiciones sanadoras de tratamiento de heridas causadas por el acne que contienen un piruvano, un antioxidante y una mezcla de acidos grasos.
DK1309589T3 (da) Ureaforbindelser og anvendelsesfremgangsmåder
ATE461698T1 (de) Gaba-analoga zur verhütung und behandlung gastrointestinaler beschwerden
DK0971713T3 (da) Anvendelse af cholinesteraseinhibitorer til behandling af opmærksomhedsforstyrrelser
CY1110113T1 (el) Φωσφολιπιδιου παραγωγα βαλπροϊκου οξεος και μειγματα αυτων
NO20030748D0 (no) Prodruger av betulinsyre for behandlingen av kreft og HIV
ES2190653T3 (es) Productos de reaccion del acido hialuronico y de aminoacidos naturales y su utilizacion en composiciones cosmeticas y farmaceuticas.
FI20011851A (fi) Fluoksetiinia tai sen happoadditiosuolaa sisältävä dispergoituva tabletti
ES2172695T3 (es) Carboxamidas y sulfonamidas de benzofurano.
DE602004017871D1 (de) Zubereitungen zur behandlung von arthritischen erscheinungen
IS6621A (is) Þíenódíbensóasúlen efnasambönd sem hindrar fyrir æxlisdrepþátt
PT994704E (pt) Utilizacao de analogos do gaba tal como a gabapentina no fabrico de um medicamento para o tratamento de doencas inflamatorias
MY133125A (en) Novel dihydroxyhexanoic acid derivatives
ES2170143T3 (es) Composiciones que comprenden halofantrina en una forma especial.
TR200101722T2 (tr) Serivastatin ve fibratların birleşimi.
BR0213099A (pt) Compostos policìclicos de 5 membros substituìdos úteis para inibição seletiva da cascata de coagulação
PT901492E (pt) Derivados do taxano, processo para a sua preparacao e as formulacoes que os contem
BR9709264A (pt) Processo para produzir e composto
TWI262791B (en) 6-methoxy-2-naphthylacetic acid prodrugs
DK1049480T3 (da) Antiviralt middel af planteoprindelse
UY26930A1 (es) Amidas de ácido fenilciclohexanocarboxílico sustituido y su uso
UY27475A1 (es) Amidas de ácido piperazinciclohexanocarboxílico sustituidas y su utilización
ATE252903T1 (de) Arzneimittel zur behandlung konvulsivischer zustände